tetano
Editor, Senior Moderator
Vaccine
. 2023 Aug 19;S0264-410X(23)00971-4.
doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print. Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Yinxia Su[SUP] 1 [/SUP], Zihao Guo[SUP] 2 [/SUP], Xiu Gu[SUP] 3 [/SUP], Shengzhi Sun[SUP] 4 [/SUP], Kai Wang[SUP] 5 [/SUP], Songsong Xie[SUP] 6 [/SUP], Shi Zhao[SUP] 7 [/SUP]
Affiliations
After the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The findings contributed to the continuous monitoring of the influenza vaccine performance across the world, especially in the "post-COVID" pandemic era.
Keywords: China; Epidemic; Influenza; Test-negative design; Vaccine effectiveness.
. 2023 Aug 19;S0264-410X(23)00971-4.
doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print. Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Yinxia Su[SUP] 1 [/SUP], Zihao Guo[SUP] 2 [/SUP], Xiu Gu[SUP] 3 [/SUP], Shengzhi Sun[SUP] 4 [/SUP], Kai Wang[SUP] 5 [/SUP], Songsong Xie[SUP] 6 [/SUP], Shi Zhao[SUP] 7 [/SUP]
Affiliations
- PMID: 37604724
- DOI: 10.1016/j.vaccine.2023.08.039
After the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The findings contributed to the continuous monitoring of the influenza vaccine performance across the world, especially in the "post-COVID" pandemic era.
Keywords: China; Epidemic; Influenza; Test-negative design; Vaccine effectiveness.